click enter text
merck report financi result tuesday compani
comfort beat consensu revenu ep
lift revenu ep guidanc
keytruda gardasil sale continu impress beat consensu
also upsid ahead view written
previous see link prior research later report
remain bullish lift estim pt
in-depth discuss mrk pipelin see
 highlight pipelin unplug call
inform stock cover see recent
report global pharmaceut juli issu monthli
trade fundament data
upsid target
factset/wolf research price juli
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
tuesday open merck
report strong result beat consensu revenu ep
lift revenu ep guidanc midpoint
post solid keytruda gardasil sale
despit saw share price close mere deserv higher view
overal impress deliv good result tuesday similar beat
revenu ep rais revenu ep guidanc strong perform broad base
two notabl driver keytruda gardasil continu think product surpris
upsid time keytruda driver ex-u opportun relev research see global
 azn ex-u opportun substanti under-model
probabl gardasil driver multi-facet global reach product continu expand
driven broader awar public health benefit offer relev research see global
 gardasil major under-appreci growth driver under-model billion
dollar apart financi result rel quiet quarter major updat confer
call content lite major disclosur pipelin new news admittedli mrk
pipelin thin exclud indic expans exist medicin howev base
busi chug along like matter less time build
combin intern develop extern busi develop bear case
increas singl product concentr risk form keytruda may appropri concern
due time loe occur decad yet earli overli concern product
still front end life cycl curv even though market alreadi realiti
fact driver growth gardasil lynparza product
recent in-depth discuss pipelin see global pharmaceut highlight
inform stock cover see recent report juli
issu monthli controversi report
term sale ep exhibit
revenu report sale vs consensu larg differ
non-gaap ep report vs consensu
keytruda sale vs consensu
januvia/janumet sale vs consensu
page
gardasil sale vs consensu well consensu
still beat estim slightli
revenu guid vs prior
pipelin materi new news announc monday keytruda met primari endpoint pcr kn-
neo-adjuv tnbc regardless statu import win depend magnitud benefit
like meaning given earli trial stoppag like registr wait event free surviv data
matur
revenu increas ep increas
revenu estim rise ep estim rise
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate increas slightli vs prior repres
peer averag growth peer average compound-annual-growth-rate balanc valuat offer growth
reason price
price target higher vs prior repres higher multipl vs prior
new ep estim rais multipl given continu execut
china strong growth lung reimburs mel
neoadjuv therapi play import role breast cancer includ tnbc suggest event free surviv
hit
 publish analysi recent show matur cancer drug commonli ex-u
sale end surpass us sale often tune yet nobodi realli seem model
lt forecast show regard would say see signific opportun
ex-u china ja market agre ex-u opportun signific realli highlight
china address whether ex-u could surpass us wolf comment analysi
page
describ compel evid concept see azn
ex-u opportun substanti under-model probabl
 light bmi success part surpris mrk program
mrk interest determin whether ad add anyth keytruda
alon done ipi intern program registr trial look
combin like nsclc
 regul like benchmark part bmi soc includ keytruda
say hard comment releas data reiter strength chemo
 keytruda rcc share excit perform point advantag
three risk group intend prescrib base use regimen point key growth driver
 see keytruda lynparza trial result start registr trial prostat soon lot
work continu done area
 keytruda china get nrdl lung wait see get invit particip
next year lung cancer patient part label indic gener also
see good uptak self-pay market
 need ef data file say discuss regul
indic whether pcr data good enough file
 deliv patient respond better better surviv would mrk
respons say difficult comment without see data remind
show benefit part
 updat keytruda lynparza/parp gener concept parp creat antigen
could help elicit immune-respons io agent remain excit idea lynparza well
toler also help outlook
lynparza patient share us lenvima driven
 sustain growth gardasil otherwis us cdc purchas gardasil boost
ex-u also remain strong ped vaccin also stock
 us gardasil much wholesal buy add would quantifi us say market
page
 work find better partner vs doravirin would will partner
compani come ideal combin say remark activ especi
implant set say noth wrong doravirin answer question
collabor compani wolf comment see recent analysi global
 slide hiv/aid paradigm shift soon
 prep timelin could shorten convent trial larg
trial larg point novel trial design would acceler
expect revenu growth opex increas mid-sd ep growth y/i
 view interest larg merger continu look bolt-on could rang
small larg chang languag
 anoth question orphan drug size size necessarili indic complex
 view neg price go forward give clariti behind assumpt
give specif answer comment histor us price increas difficult
 gross margin one driver bmi royalti reduct driver expect
gener flat look forward neg price impact royalti collabor
quantifi
 view sfc propos reiter appear standard industri parti line
lower cost patient counter also catastroph lynparza part remind keytruda
part feel balanc across government channel
 elabor china dynam drive growth china repres total sale driven
wide rang product
 nuvar noth new happen product
page
exhibit show compani report actual result vs estim consensu
exhibit merck result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit merck guidanc vs wr estim old new
page
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement pharma anim oper incom income/ expens incom outstand margin total margin incom oper
page
exhibit wr merck balanc sheet cash flow statement
page
flow statement incom incom chang asset flow oper activ secur subsidiari sale secur subsidiari flow invest activ chang short-term treasuri paid flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr paid-in comprehens treasuri stock merck sharehold sharehold liabil sharehold
